AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NYSE:MEDMedifast Stock Price, Forecast & News

$149.47
+0.56 (+0.38 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$147.88
Now: $149.47
$151.30
50-Day Range
$91.52
MA: $115.27
$149.82
52-Week Range
$49.03
Now: $149.47
$157.98
Volume431,622 shs
Average Volume293,992 shs
Market Capitalization$1.76 billion
P/E Ratio23.76
Dividend Yield3.04%
Beta1.27
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Read More
Medifast logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
CUSIP58470H10
Phone410-581-8042

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$713.67 million
Cash Flow$6.64 per share
Book Value$9.03 per share

Profitability

Net Income$77.92 million

Miscellaneous

Employees420
Market Cap$1.76 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Medifast (NYSE:MED) Frequently Asked Questions

How has Medifast's stock been impacted by COVID-19 (Coronavirus)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MED shares have increased by 112.2% and is now trading at $149.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medifast?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medifast.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Medifast.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) announced its earnings results on Tuesday, May, 5th. The specialty retailer reported $1.93 earnings per share for the quarter, topping analysts' consensus estimates of $1.33 by $0.60. The specialty retailer had revenue of $178.46 million for the quarter, compared to the consensus estimate of $161.90 million. Medifast had a net margin of 10.41% and a return on equity of 65.66%. View Medifast's earnings history.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Tuesday, June 16th. Investors of record on Tuesday, June 30th will be paid a dividend of $1.13 per share on Thursday, August 6th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Monday, June 29th. View Medifast's dividend history.

What price target have analysts set for MED?

4 brokerages have issued twelve-month price targets for Medifast's stock. Their forecasts range from $86.00 to $164.00. On average, they anticipate Medifast's share price to reach $113.33 in the next twelve months. This suggests that the stock has a possible downside of 24.2%. View analysts' price targets for Medifast.

Has Medifast been receiving favorable news coverage?

News stories about MED stock have trended negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medifast earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the specialty retailer a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Medifast.

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Boeing (BA), Mastercard (MA), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Paypal (PYPL) and Baidu (BIDU).

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Mr. Daniel R. Chard, CEO & Director (Age 54)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
  • Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.05%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View institutional ownership trends for Medifast.

Which institutional investors are buying Medifast stock?

MED stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer. View insider buying and selling activity for Medifast.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $149.47.

How big of a company is Medifast?

Medifast has a market capitalization of $1.76 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.